What is the rating for BFRI stock?

Biofrontera Inc. (BFRI) has a "Reduce" rating based on our 6-factor quantitative model. It has a composite score of 44.9 and ranks #2816 out of 7,333 stocks in our coverage universe with a 2-star rating.

Is BFRI a good stock to buy?

Based on our quantitative analysis, BFRI receives a "Reduce" rating with 2 out of 5 stars. Key factors include: Quality score of 53.2, Value score of 16, and Momentum score of 35.3. The timing score is 52, indicating "Neutral" entry conditions. This is not investment advice - please conduct your own research.

What sector is BFRI in?

Biofrontera Inc. (BFRI) operates in the Manufacturing sector, specifically in the Pharmaceutical Products industry. It has a market capitalization of $0.01 billion.

What is BFRI's P/E ratio?

P/E ratio data is not currently available for BFRI.

Does BFRI pay a dividend?

BFRI does not currently pay a dividend.

What is BFRI's market cap?

Biofrontera Inc. (BFRI) has a market capitalization of $0.01 billion, making it a micro-cap stock.

What are the risks of investing in BFRI?

Key risk factors for BFRI include: higher volatility, and general market risk. As with all investments, there is risk of loss.

How does BFRI compare to peers?

Within the Manufacturing sector, BFRI ranks #2816 overall with a quality score of 53.2/100 and value score of 16/100.

What is BFRI's revenue growth?

BFRI has revenue growth of -10.9% year-over-year.

What is BFRI's composite score?

Biofrontera Inc. (BFRI) has a composite score of 44.9/100, which places it at rank #2816 out of 7,333 stocks. This score is derived from our proprietary 6-factor quantitative model that evaluates quality, value, momentum, investment efficiency, stability, and short interest.

How does BFRI compare to the S&P 500?

BFRI ranks in the top 62% of all stocks in our coverage universe with a composite score of 44.9.

What are the bull and bear cases for BFRI?

Bull case: BFRI scores highest in short interest at 85.9/100, indicating strong performance in this area. Bear case: The weakest factor is value at 16/100, which may present a risk. Our overall assessment is Reduce with 2 out of 5 stars.

Is BFRI overvalued or undervalued?

BFRI appears overvalued based on our value factor score of 16/100.

What is BFRI's momentum score?

BFRI has a momentum score of 35.3/100, placing it in the weak category. This suggests recent price weakness and potential selling pressure.

When is BFRI's next earnings date?

For the latest earnings date and analysis for BFRI, visit our earnings calendar or check the BFRI stock page for real-time updates. Our AI-generated earnings reports provide in-depth analysis after each quarterly report.

Is BFRI a good stock to buy right now?

Based on our 6-factor quantitative model, Biofrontera Inc. (BFRI) receives a "Reduce" rating with a composite score of 44.9/100. It is ranked #2816 out of 7,333 stocks. Key factor scores: Quality 53/100, Value 16/100, Momentum 35/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for BFRI?

Biofrontera Inc. (BFRI) has a "Reduce" rating and 2-star score. The composite score of 44.9 ranks it #2816 among 7,333 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is BFRI in?

Biofrontera Inc. operates in the Manufacturing sector (Pharmaceutical Products industry) with a market cap of $11 million. It is classified as a micro-cap stock.

Does BFRI pay a dividend?

BFRI does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is BFRI's P/E ratio?

P/E ratio data is not currently available for BFRI, which may indicate the company is not yet profitable.

How profitable is BFRI?

BFRI's quality factor score is 53/100. Gross margin: 70.7%. ROE: -1738.0% vs sector average -1.9%. High margins suggest pricing power and competitive moats.

How is BFRI valued compared to peers?

BFRI's value factor score is 16/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is BFRI's debt level?

Debt data is not available for BFRI.

BFRI has a beta of 1.18, meaning it tracks the market. Stability score: 40/100.

Does BFRI have high short interest?

BFRI's short interest factor score is 86/100 (higher = less short selling). Very low short interest — broad institutional consensus.

BFRI Stock Analysis — Biofrontera Inc. Price Target & Forecast 2026

IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.

HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.

RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.

BFRI Stock Analysis — Biofrontera Inc. Price Target & Forecast 2026 | Blank Capital Research

Sector

Manufacturing

Industry

Pharmaceutical Products

Market Cap

$11M

Leadership

Erica L. Monaco

Business Summary

Biofrontera Inc. engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device. The RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

Operations

Headcount

Location

HQ Base

Pending Verification

Fundamental Spot Check

Context: 2025

Valuation

Market Cap

$11M

P/E Ratio

P/B Ratio

P/S Ratio

0.31xOutperforming

EV/EBITDA

Dividend Yield

0.00%

Efficiency & Risk

Gross Margin

70.7%Outperforming

Operating Margin

-63.5%Lagging

ROE

-1738.0%Lagging

Rev Growth (YoY)

-10.9%

Debt/Equity

Beta

1.18

Red = Sector Laggard

Black = Market Average

Revenue Breakdown

Strategic Timing Audit

WEAK

0/6

Negative Alignment — Extreme Caution

Quantitative Factor Convergence Analysis Verified

Momentum

35th pctl

Intelligence Feed

yahooFeb 17 Neutral

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunkSupplemental NDA submission for extremities, neck and trunk indication expected in Q3 2026 WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photo

yahooFeb 11 Negative

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the USBCC is the most common skin cancer in the US with 3.6 million cases diagnosed annually1 WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercializatio

finance.yahoo.comFeb 9 Positive

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel (p<0.0003)Actinic keratosis (AK) is the most common skin condition diagnosed by US dermatologists1If left untreated, AK may progress to squamous cell carcinoma2,3 WOBURN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic

zacks.comFeb 5 Negative

Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year?

Zacks Investment ResearchMay 13 Negative

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 54.55% and 88.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Earnings Call Transcripts

Unlock Valuation Tools

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Financial Intelligence Ledger

Verified SEC Filings Aggregate • BFRI

Export

Metric Entity	10Y Historical Trend	2024	2023	2022	2021	2020
Revenue		$37M9.5%	$34M18.8%	$29M19.0%	$24M27.9%	$19M
Cost of Revenue	-	—	—	—	—	$0
Gross Profit	-	—	—	—	—	$19M
R&D Expense	-	$2M	—	—	—	—
Operating Expenses	-	—	—	—	—	$28M
Operating Income		-$17M24.1%	-$23M22.0%	-$19M26.3%	-$25M162.3%	-$10M
Interest Expense		—	$220K12.8%	$195K43.3%	$344K88.0%	$3M
Tax Provision		$22K57.1%	$14K56.3%	$32K42.9%	$56K12.5%	$64K
EBITDA		-$17M26.8%	-$23M22.0%	-$19M26.3%	-$25M236.4%	-$7M
Net Income		-$18M11.8%	-$20M	-$640K98.3%	-$38M243.3%	-$11M
EPS (Diluted)		$-3.2275.3%	$-13.02	$-0.03	-	$-479.48

SEC EDGAR Repository

Direct unfiltered access to 10-K, 10-Q and 8-K filings for BFRI.

Open Regulatory Dossier

Data Integrity Notice

Figures adjusted for stock splits and restatements where applicable.

TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.

Execution Benchmarks Audit

Revenue Growth

YOY expansion rate

-263% SCTR

-10.9%

Sector Avg: 6.7%

Gross Margin

Core pricing power

+61% SCTR

70.7%

Sector Avg: 44.1%

Operating Margin

Operating efficiency

-2631% SCTR

-63.5%

Sector Avg: 2.5%

Return on Equity

Equity efficiency

+91371% SCTR

-1738.0%

Sector Avg: -1.9%

Dividend Yield

Direct cash return

-NaN% SCTR

0.0%

Sector Avg: 0.0%

Financial History

Forensic Accounting Audit

Audit Required

Asset Efficiencymedium RISK

Material decline in asset turnover efficiency detected

Margin Integritymedium RISK

High margin volatility — erratic forensic earnings quality

Algorithmic red flag detection based on regulatory SEC filings.

Unlock Financial Statements

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Shareholder Returns

Capital Allocation audit

Smart Money Conviction

Neutral

Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.

Governance Audit

Weak Index

WeakModerateStrong

Lower quality and stability scores may indicate governance concerns. Verified against factor-based integrity benchmarks.

Executive Operations

CEO: Erica L. Monaco

Insider alignment Audit

No recent insider transactions available for BFRI

Major Institutional Blocks

Top 5 Holders

Institutional cap table data requires verified 13F filing feeds.

Access SEC 13F Dossier →

Form 4 Filings

Recent Activity

Insider transaction data currently awaiting regulatory verification.

Access SEC Form 4 Dossier →

Regulatory Disclosure Vault

Proxy Statement (DEF 14A)

Exec Comp, Board Nominees, Proposals

Annual Report (10-K)

MD&A, Risk Factors, Strategy

Institutional Holders (13F)

Loading institutional data...

Insider Liquidity

Short Interest audit

SEC Risk Factors

Unlock Governance & Ownership

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Factor Analysis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Investment Thesis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Institutional Peer Matrix

Top Manufacturing Universe

Stock	Rating	Score▼	Quality	Value	Momentum	P/E	EV/EBITDA	ROE	ROA	Gross Mgn	Op Mgn	Net Mgn	Rev Growth	Div Yield	D/E	Mkt Cap	AUDIT
$UL UNILEVER PLC		78	96	98	59	-	-	-	-	-	-	-	-	-	-	$0	VS
$ASML ASML HOLDING NV		77	89	86	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$ESLT ELBIT SYSTEMS LTD		76	81	87	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$MT ArcelorMittal		75	71	98	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$AMAT APPLIED MATERIALS INC /DE		75	85	87	84	20.9x	13.6x	32.9%	20.5%	48.8%	30.6%	24.4%	7.7%	0.9%	32.0x	$148.6B	VS
$SIMO Silicon Motion Technology CORP		75	84	86	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$CODA Coda Octopus Group, Inc.		74	83	90	79	16.3x	11.9x	7.4%	7.5%	68.3%	19.5%	18.2%	29.0%	0.0%	0.0x	$84M	VS
$GSK GSK plc		74	84	90	70	-	-	-	-	-	-	-	-	-	-	$0	VS
$EFXT Enerflex Ltd.		74	80	91	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$BUD Anheuser-Busch InBev SA/NV		74	84	97	63	-	-	-	-	-	-	-	-	-	-	$0	VS
$BFRI Biofrontera Inc.		45	53	16	35	-	-	-1738.0%	-141.7%	70.7%	-63.5%	-66.5%	-10.9%	0.0%	-	$11M
SECTOR BENCH	-	-	-	-	-	22.3x	11.5x	-1.9%	0.9%	44.1%	2.5%	1.0%	6.7%	0.0%	0.2x	-	REF

Access Full Manufacturing Intelligence Archive →

Lateral Comparison Mesh

$BFRI / $UL AUDIT $BFRI / $ASML AUDIT $BFRI / $ESLT AUDIT $BFRI / $MT AUDIT $BFRI / $AMAT AUDIT

Market Intelligence FAQ

Biofrontera Inc. (BFRI) receives a "Reduce" rating with a composite score of 44.9/100. It ranks #2816 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.

Full Research Publication

Equity Research Analysis: Biofrontera Inc. (BFRI)

FEBRUARY 2026|Blank Capital Research Unit|Spot: $0.83

Price$0.83

Composite Score44.9/100

RatingREDUCE (2★)

Rank#2816 OF 7,333

Market Cap$11M

ROE

Comments

Institutional Audit

Feb 25, 2026

Biofrontera Inc.

44.9

Executive Summary

Biofrontera Inc. receives a Reduce rating from our analysis, with a composite score of 44.9/100 and 2 out of 5 stars, ranking #2816 out of 7,333 stocks. BFRI's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.

Business Quality

With a quality score of 53/100, BFRI shows adequate but unremarkable business quality. The company reports a return on equity of -1738.0% (sector avg: -1.9%), gross margins of 70.7% (sector avg: 44.1%), net margins of -66.5% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.

Intrinsic Valuation

BFRI registers a value score of just 16/100, suggesting the stock trades at a significant premium to its fundamental metrics. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.

Capital Reinvestment

Biofrontera Inc.'s investment score of 34/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -10.9% vs. a sector average of 6.7% and a return on assets of -141.7% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.

Market Momentum

BFRI is currently showing below-average momentum at 35/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -10.9% year-over-year, while a beta of 1.18 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.

Balance Sheet Health

BFRI's stability score of 40/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.18. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.

Institutional Risk Profile

BFRI's short interest factor score of 86/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include micro-cap liquidity risk. As a micro-cap company with a market capitalization of $11M, Biofrontera Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.

Sector Benchmark Analysis

Biofrontera Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2816 of 7,333 overall (62nd percentile). Key comparisons include ROE of -1738.0% trailing the -1.9% sector median and operating margins of -63.5% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.

Comparative Research Mesh

BFRI VS S&P 500 (SPY)TOP MANUFACTURING PEERS

Strategic Alternatives

While BFRI currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.

View Top Manufacturing Alpha →

BFRI

Biofrontera Inc.

Business Summary

Operations

Location

Fundamental Spot Check

Valuation

Efficiency & Risk

Intelligence Feed

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year?

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

Unlock Valuation Tools

Unlock Financial Statements

Unlock Governance & Ownership

Unlock Factor Analysis

Unlock Investment Thesis

Lateral Comparison Mesh

Comments

Unlock Performance & Technicals

Economic Moat Audit

Economic Value Creation

Margin Superiority

Reinvestment Efficiency

Growth Durability

Financial Resilience

Uncertainty Audit

01Executive Summary

02Strategy & Outlook

Risk / Reward Variance

Research Verdict

Related Stocks

Executive Summary

Business Quality

Intrinsic Valuation

Capital Reinvestment

Market Momentum

Balance Sheet Health

Institutional Risk Profile

Sector Benchmark Analysis

Comparative Research Mesh

Strategic Alternatives

Factor Dispersion Audit

Sector Variance Findings

Market Intel

Intelligence Feed

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year?

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates